Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group

European Journal of Cancer ◽

10.1016/j.ejca.2006.10.009 ◽

2007 ◽

Vol 43 (2) ◽

pp. 331-340 ◽

Cited By ~ 9

Author(s):

Leilani Morales ◽

Peter Canney ◽

Jaroslaw Dyczka ◽

Emiel Rutgers ◽

Robert Coleman ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Operable Breast Cancer ◽

Phase Iii ◽

Adjuvant Tamoxifen ◽

Postoperative Adjuvant Chemotherapy ◽

Phase Iii Trial ◽

European Organisation ◽

Cancer Breast ◽

Breast Group

Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djr351 ◽

2011 ◽

Vol 103 (20) ◽

pp. 1529-1539 ◽

Cited By ~ 21

Author(s):

Davide Bedognetti ◽

Mario Roberto Sertoli ◽

Paolo Pronzato ◽

Lucia Del Mastro ◽

Marco Venturini ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Hormone Therapy ◽

Phase Iii ◽

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

10.1158/0008-5472.sabcs11-s4-8 ◽

2011 ◽

Cited By ~ 19

Author(s):

L Gianni ◽

G Romieu ◽

M Lichinitser ◽

S Serrano ◽

M Mansutti ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

First Results ◽

Locally Recurrent

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial

Annals of Oncology ◽

10.1093/annonc/mdg117 ◽

2003 ◽

Vol 14 (3) ◽

pp. 414-420 ◽

Cited By ~ 141

Author(s):

G. Mustacchi ◽

R. Ceccherini ◽

S. Milani ◽

A. Pluchinotta ◽

A. De Matteis ◽

...

Keyword(s):

Breast Cancer ◽

The Elderly ◽

Operable Breast Cancer ◽

Phase Iii ◽

Long Term Results ◽

Adjuvant Tamoxifen ◽

Randomized Controlled

A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in ‘tAnGo’: A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide (EC)-based, adjuvant chemotherapy (CT) for early stage breast cancer

10.1200/jco.2004.22.90140.821 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 821-821

Author(s):

C. J. Poole ◽

H. C. Howard ◽

L. Hiller ◽

J. A. Dunn ◽

A. M. Wardley ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Early Stage ◽

Hepatic Function ◽

Early Stage Breast Cancer ◽

Phase Iii ◽

Prospective Evaluation ◽

A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study.

10.1200/jco.2016.34.15_suppl.4000 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4000-4000 ◽

Cited By ~ 36

Author(s):

Marcel Verheij ◽

Edwin PM Jansen ◽

Annemieke Cats ◽

Nicole C.T. van Grieken ◽

Neil K Aaronson ◽

...

Keyword(s):

Gastric Cancer ◽

Adjuvant Chemotherapy ◽

Phase Iii ◽

Phase Iii Trial ◽

First Results ◽

Resectable Gastric Cancer ◽

Neo Adjuvant Chemotherapy

Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278)

Clinical Breast Cancer ◽

10.3816/cbc.2008.n.056 ◽

2008 ◽

Vol 8 (5) ◽

pp. 453-456 ◽

Cited By ~ 38

Author(s):

Valentina Guarneri ◽

Antonio Frassoldati ◽

Paolo Bruzzi ◽

Roberto D'Amico ◽

Maurizio Belfiglio ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Trial ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

P104 Adjuvant chemotherapy plus alternated hormonal therapy (AVCF-TM) for HR+ N+ breast cancer: 13-year results of a randomized phase III trial

European Journal of Cancer ◽

10.1016/s0959-8049(97)89321-5 ◽

1998 ◽

Vol 34 ◽

pp. S40-S41

Author(s):

M. Di Palma ◽

S. Delaloge ◽

S. Guérin ◽

P. Fargeot ◽

T. Conroy ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Hormonal Therapy ◽

Phase Iii ◽

Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041).

10.1200/jco.2010.28.15_suppl.594 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 594-594 ◽

Cited By ~ 3

Author(s):

A. Buzdar ◽

V. Suman ◽

F. Meric-Bernstam ◽

J. C. Boughey ◽

A. M. Leitch ◽

...

Keyword(s):

Breast Cancer ◽

Safety Data ◽

Operable Breast Cancer ◽

Phase Iii ◽

Her2 Positive ◽

Foxp3 expression in breast cancer cells: A new predictor of response to anthracycline versus docetaxel in primary breast cancer treated with adjuvant chemotherapy in the phase III trial FNCLCC/PACS-01.

10.1200/jco.2011.29.15_suppl.1026 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 1026-1026

Author(s):

F. Ghiringhelli ◽

P. Fumoleau ◽

L. Arnould ◽

G. Mignot ◽

C. Dalban ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Cancer Cells ◽

Primary Breast Cancer ◽

Breast Cancer Cells ◽

Foxp3 Expression ◽

Phase Iii ◽